DCVMN COVID-19 Committee

SURVEY FINDINGS AND NEXT STEPS
Survey objectives

1) Evaluate the effectiveness of the committee in achieving its objectives

2) Gather descriptive feedback from committee members and observers

3) Identify gaps/weaknesses of committee meetings and/or objectives

4) Facilitate discussion among members and observers
   → realign objectives, committee organization and workplan
Survey respondents

7 anonymous responses to the survey:

Has your organization been engaged in COVID-19 vaccine development

- Yes: 6
- No: 1

Has your organization been engaging in a tech transfer, licensing agreement or joint venture to manufacturer COVID-19 vaccines?

- Yes: 7
- No: 0
The objectives of the COVID-19 committee

- Evaluating prime COVID-19 vaccine candidates
- Discussing and evaluating technical information
- Discussing solutions provided by stakeholder organizations
- Assessing and sharing information on technologies
- Developing solid bases for statements to support DCMVN dialogue
The objectives of the COVID-19 committee (aggregate scores)

<table>
<thead>
<tr>
<th>Objective</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discussing solutions provided by organizations</td>
<td>18</td>
</tr>
<tr>
<td>Evaluating prime COVID-19 vaccine candidates</td>
<td>19</td>
</tr>
<tr>
<td>Discussing and evaluating technical information</td>
<td>20</td>
</tr>
<tr>
<td>Assessing and sharing information on technologies</td>
<td>21</td>
</tr>
<tr>
<td>Developing solid bases for statements to support DCVMN dialogue</td>
<td>21</td>
</tr>
</tbody>
</table>
Qualitative insights - Benefits

Are there benefits?

- Provides geographic overview of COVID-19 vaccines and players
- Opportunity to share experiences from different companies and countries
- Learning from each other + share best practices

- No impact on the decisions made by stakeholders
- Members are not aware of the actions being taken by the network (or elected network members) in various forums.
- The committee was formed to formulate opinions (on topics such vaccine distribution) and circulate them to stakeholders. This has not been effectively undertaken or communicated
Qualitative insights – What needs to be addressed

Topics mentioned by respondents

- Epidemiological updates (variants) - 1
- Vaccine distribution - 1
- Funding opportunities - 1
- Analytical methods - 1
- Pharmacovigilance - 1
- Platform technologies and tech transfers - 2
- Regulatory requirements - 2
- Vaccine landscape (incl. those for variants) + next gen vaccines - 3
- Clinical Trials and efficacy studies of registered vaccines - 3

Frequency
Qualitative insights – challenges faced in introducing COVID-19 vaccine product

**Funding**
- Internal development
- For ‘at risk’ manufacturing prior to licensure
- Adjuvant access

**Regulatory hurdles**
- Government regulations
- NRAs regulations not fit to pandemic situation
- Regulation standards of new production processes

**Up-scaling**
- Scaling up manufacturing
- Implementing new production processes
Committee meetings: efficiency & frequency

<table>
<thead>
<tr>
<th>Are meetings conducted in a clear and efficient manner</th>
<th>No more</th>
<th>Yes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

“Difficult to answer”

“More like coffee corner talk than a meeting”

“In the initial meetings, only the obvious and rampant information from the media was discussed. We did not think about actual objectives”.

<table>
<thead>
<tr>
<th>Preferred frequency of committee meetings</th>
<th>Quarterly</th>
<th>Monthly</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2</td>
<td>5</td>
</tr>
</tbody>
</table>

“Depends on the quality”
Additional comments

“Surveys like this are really very important for us to try to rescue Committee members who, over time, ended up not prioritizing their participation in the Committee. Perhaps by bringing more attractive subjects to the Committee's agenda, these members will be more interested in participating”.

“We need to have meetings involving various working groups in the DCVMN. Each working group has a key role to play during this pandemic. The more minds we can involve the better”.

“COVID-19 is very broad topic. It is quite difficult to expect to cover all aspects. All members have their own work and cannot fully focus”.